UNLABELLED: This study evaluated the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamate, in patients with HER2-negative, metastatic breast cancer who had received 0 or 1 prior lines of chemotherapy. Although CT-2103 had activity in this small study, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected, and led to early termination of the trial. PURPOSE: To evaluate the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamate, in patients with metastatic breast cancer who had received 0 or 1 prior lines of chemotherapy. PATIENTS AND METHODS: Eighteen women with HER2-negative breast cancer were enrolled. Patients received intravenous CT-2103 at a dose of 175 mg/m2 of conjugated paclitaxel over 10 min every 3 weeks, without routine premedication. Eighty-three percent of women had received prior chemotherapy as part of adjuvant (39%), metastatic (17%), or both adjuvant and metastatic (28%) treatment. Three patients (17%) had previously received a taxane in the adjuvant setting. RESULTS: Objective responses were observed in 4 of 18 patients (overall response rate, 22%, 95% confidence interval, 6 to 48%). Grade 3 or 4 neuropathy was observed in four patients. Grade 3 or 4 hypersensitivity reactions (HSR) were observed in four patients; none occurred prior to cycle 4 of therapy. Because of the higher-than-expected rate of HSR, the study was terminated early. CONCLUSION: Although CT-2103 had activity in this small study of women with HER2-negative metastatic breast cancer, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected. Hypersensitivity reactions were most likely to occur in later cycles of treatment, suggesting a true drug allergy, distinct from the HSR typically seen with standard paclitaxel.
UNLABELLED: This study evaluated the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamate, in patients with HER2-negative, metastatic breast cancer who had received 0 or 1 prior lines of chemotherapy. Although CT-2103 had activity in this small study, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected, and led to early termination of the trial. PURPOSE: To evaluate the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamate, in patients with metastatic breast cancer who had received 0 or 1 prior lines of chemotherapy. PATIENTS AND METHODS: Eighteen women with HER2-negative breast cancer were enrolled. Patients received intravenous CT-2103 at a dose of 175 mg/m2 of conjugated paclitaxel over 10 min every 3 weeks, without routine premedication. Eighty-three percent of women had received prior chemotherapy as part of adjuvant (39%), metastatic (17%), or both adjuvant and metastatic (28%) treatment. Three patients (17%) had previously received a taxane in the adjuvant setting. RESULTS: Objective responses were observed in 4 of 18 patients (overall response rate, 22%, 95% confidence interval, 6 to 48%). Grade 3 or 4 neuropathy was observed in four patients. Grade 3 or 4 hypersensitivity reactions (HSR) were observed in four patients; none occurred prior to cycle 4 of therapy. Because of the higher-than-expected rate of HSR, the study was terminated early. CONCLUSION: Although CT-2103 had activity in this small study of women with HER2-negative metastatic breast cancer, neurotoxicity and hypersensitivity reactions were more frequent in this patient population than expected. Hypersensitivity reactions were most likely to occur in later cycles of treatment, suggesting a true drug allergy, distinct from the HSR typically seen with standard paclitaxel.
Authors: S E Jones; J Erban; B Overmoyer; G T Budd; L Hutchins; E Lower; L Laufman; S Sundaram; W J Urba; K I Pritchard; R Mennel; D Richards; S Olsen; M L Meyers; P M Ravdin Journal: J Clin Oncol Date: 2005-08-20 Impact factor: 44.544
Authors: J M Nabholtz; K Gelmon; M Bontenbal; M Spielmann; G Catimel; P Conte; U Klaassen; M Namer; J Bonneterre; P Fumoleau; B Winograd Journal: J Clin Oncol Date: 1996-06 Impact factor: 44.544
Authors: Nuhad K Ibrahim; Brian Samuels; Ray Page; Dinesh Doval; Kirtikumar M Patel; S C Rao; Madhavan Krishnan Nair; Paul Bhar; Neil Desai; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: A Polyzos; N Tsavaris; C Kosmas; T Arnaouti; N Kalahanis; C Tsigris; A Giannopoulos; G Karatzas; L Giannikos; P P Sfikakis Journal: Oncology Date: 2001 Impact factor: 2.935
Authors: S Chan; K Friedrichs; D Noel; T Pintér; S Van Belle; D Vorobiof; R Duarte; M Gil Gil; I Bodrogi; E Murray; L Yelle; G von Minckwitz; S Korec; P Simmonds; F Buzzi; R González Mancha; G Richardson; E Walpole; M Ronzoni; M Murawsky; M Alakl; A Riva; J Crown Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: R Paridaens; L Biganzoli; P Bruning; J G Klijn; T Gamucci; S Houston; R Coleman; J Schachter; A Van Vreckem; R Sylvester; A Awada; J Wildiers; M Piccart Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: A D Seidman; A Tiersten; C Hudis; M Gollub; S Barrett; T J Yao; J Lepore; T Gilewski; V Currie; J Crown Journal: J Clin Oncol Date: 1995-10 Impact factor: 44.544
Authors: Eric P Winer; Donald A Berry; Susan Woolf; David Duggan; Alice Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark L Graham; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Xinghe Wang; Gang Zhao; Sang Van; Nan Jiang; Lei Yu; David Vera; Stephen B Howell Journal: Cancer Chemother Pharmacol Date: 2009-07-11 Impact factor: 3.333